Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19033476 | 0.88 | MMP2 (0.53) | CTSSCTSKCTSLCTSBOPRK1 | |
| SCHEMBL31525044 | 0.84 | CTSK (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL29477122 | 0.84 | SLC7A5 (0.54) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL18912852 | 0.83 | CTSS (0.50) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL31293776 | 0.82 | OPRD1 (0.55) | CTSSCTSKOPRK1MMP1MMP3 | |
| SCHEMBL30064540 | 0.82 | OPRD1 (0.53) | CTSSCTSKCTSLCTSBOPRK1 | |
| SCHEMBL8398270 | 0.82 | CTSC (0.44) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL29498364 | 0.81 | ACE (0.48) | CTSSCTSKCTSLCTSBCTSC | |
| SCHEMBL17154025 | 0.81 | CTSS (0.51) | CTSSCTSKCTSLCTSBMMP1 | |
| SCHEMBL19033465 | 0.81 | MMP1 (0.46) | CTSSCTSKCTSLCTSBMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381112-A1 | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ | VACCITECH NORTH AMERICA, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| EP-4216927-A1 | COMPOSITIONS AND METHODS OF MANUFACTURING AMPHIPHILIC BLOCK COPOLYMERS THAT FORM NANOPARTICLES IN SITU | Vaccitech North America, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066635-A1 | COMPOSITIONS AND METHODS OF MANUFACTURING AMPHIPHILIC BLOCK COPOLYMERS THAT FORM NANOPARTICLES IN SITU | AVIDEA TECHNOLOGIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381112-A1 | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ | SBDS, MTDH, DLST | CTSS 780/4885CTSK 3799/4885CTSL 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.